Gene ther­a­py biotech Alveo­Gene launch­es with lentivi­ral plat­form for res­pi­ra­to­ry dis­eases

New com­pa­ny Alveo­Gene, backed by ex­perts at the UK Res­pi­ra­to­ry Gene Ther­a­py Con­sor­tium (GTC), has made its de­but with a lead pro­gram for rare res­pi­ra­to­ry dis­ease al­pha-1 an­tit­rypsin de­fi­cien­cy (AATD).

Ox­ford Sci­ence En­ter­pris­es cre­at­ed the com­pa­ny to­geth­er with Har­ring­ton Dis­cov­ery In­sti­tute, Old Col­lege Cap­i­tal and six GTC sci­en­tists. The UK biotech has an ex­clu­sive li­cense to the GTC’s next-gen­er­a­tion lentivi­ral de­liv­ery plat­form, In­Ge­nu­iTy, ex­cept with re­gard to the CFTR gene, which is mu­tat­ed in cys­tic fi­bro­sis. Boehringer In­gel­heim has tak­en the reins on that gene and is work­ing on a CF gene ther­a­py can­di­date us­ing the tech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER